KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Accumulated Expenses (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Other Accumulated Expenses data on record, last reported at $428.3 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 17.99% year-over-year to $428.3 million; the TTM value through Dec 2025 reached $428.3 million, up 17.99%, while the annual FY2025 figure was $428.3 million, 17.99% up from the prior year.
  • Other Accumulated Expenses reached $428.3 million in Q4 2025 per VRTX's latest filing, down from $441.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $648.6 million in Q1 2024 and bottomed at $201.4 million in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $348.8 million, with a median of $336.9 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: soared 72.04% in 2024, then plummeted 40.43% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $268.4 million in 2021, then increased by 16.06% to $311.5 million in 2022, then skyrocketed by 69.25% to $527.2 million in 2023, then plummeted by 31.15% to $363.0 million in 2024, then rose by 17.99% to $428.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $428.3 million in Q4 2025, $441.5 million in Q3 2025, and $425.4 million in Q2 2025.